A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.
SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99
Vital medical radioisotope used in over 40,000 medical diagnostic procedures in the United States every day SHINE’s Mo-99 production facility steadily progressing construction in Janesville, Wis.Credit: SHINE Technologies LLC [...]
SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.
SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.
SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.
SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE by October 2021. SHINE’s application for a license to operate the medical isotope production facility that it is building in Janesville, Wis., was accepted and docketed by the NRC last October.
SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) has begun its detailed technical review of SHINE’s application to operate the medical isotope production facility the company is building in Janesville, Wis.
Phoenix and SHINE Achieve New World Record for Strongest Nuclear Fusion Reaction in a Steady-State System. Leading nuclear technology companies collaborating to help turn nuclear weapons into medicine and help a billion patients. Breakthrough has potential to transform medical isotope production, solve a global health care shortage, provide a stepping stone to cleaner, safer, more abundant energy
SHINE Medical Technologies LLC today announced it has received a $15-million award from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The award was made by the agency as part of its effort to establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), the most commonly used medical isotope.
SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.